Clinical Trial Update: A Safety Study of Eptifibatide in Patients With Sickle Cell Disease [Phase 1, Phase 2]

View source ↗

Summary

This document reports the termination of a Phase 1/2 safety study of eptifibatide in patients with sickle cell disease. Results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Integrilin (Eptifibatide)

Snippet

Sponsor: University of North Carolina, Chapel Hill | Conditions: Sickle Cell Disease | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2013-06-27